Blue Water Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 17, 2023 at 05:23 pm EST
Share
Blue Water Biotech, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 5.35 million compared to USD 3.87 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to USD 0.27 a year ago.
For the nine months, net loss was USD 15.06 million compared to USD 10.2 million a year ago. Basic loss per share from continuing operations was USD 0.92 compared to USD 0.94 a year ago.
Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patientâs regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.